Holistic prevention and management of physical health side-effects of psychotropic medication: second report of the Lancet Psychiatry Physical Health Commission
Halstead S. et al, (2025), Lancet Psychiatry, 12, 673 - 699
Hormone replacement therapy helps prevent psychotic relapse during menopause
Brand B., (2025), Tijdschrift Voor Psychiatrie, 67
Genetic variants in COMT and ESR1 genes shape treatment response to raloxifene in schizophrenia-spectrum disorders.
Brand BA. et al, (2025), Psychoneuroendocrinology, 172
Antipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognition.
Brand BA. et al, (2024), Arch Womens Ment Health, 27, 931 - 941
Psychiatrists effect on positive symptom severity and daily functioning during pharmacotherapy for first-episode psychosis patients.
de Beer F. et al, (2024), Sci Rep, 14
Correction to: Evidence‑Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.
Brand BA. et al, (2024), Curr Psychiatry Rep, 26, 550 - 551
Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder.
Brand BA. et al, (2024), Am J Psychiatry, 181, 893 - 900
The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: Divergent effects of testosterone and estrogen.
Hamers IMH. et al, (2024), Schizophr Res, 270, 273 - 280
Sex differences need to be considered when treating women with psychotropic drugs.
Sommer IE. et al, (2024), World Psychiatry, 23, 151 - 152
Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium.
Koops S. et al, (2024), Schizophr Bull, 50, 5 - 8
The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial.
Brand BA. et al, (2023), Schizophr Bull, 49, 1579 - 1590
Evidence-Based Recommendations for the Pharmacological Treatment of Women with Schizophrenia Spectrum Disorders.
Brand BA. et al, (2023), Curr Psychiatry Rep, 25, 723 - 733
Antipsychotic medication for women with schizophrenia spectrum disorders - CORRIGENDUM.
Brand BA. et al, (2023), Psychol Med, 53
Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis.
Oomen PP. et al, (2023), Psychol Med, 53, 2317 - 2327
Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse.
Sommer IE. et al, (2023), Schizophr Bull, 49, 136 - 143
[Antipsychotic drugs for women: a narrative review and clinical guidelines].
de Boer JN. et al, (2023), Tijdschr Psychiatr, 65, 87 - 94
Towards better care for women with schizophrenia-spectrum disorders.
Brand BA. et al, (2022), Lancet Psychiatry, 9, 330 - 336
Antipsychotic medication for women with schizophrenia spectrum disorders.
Brand BA. et al, (2022), Psychol Med, 52, 649 - 663
Characterizing speech heterogeneity in schizophrenia-spectrum disorders.
Oomen PP. et al, (2022), J Psychopathol Clin Sci, 131, 172 - 181
Medication strategies in first episode psychosis patients: A survey among psychiatrists.
Kikkert MJ. et al, (2022), Early Interv Psychiatry, 16, 139 - 146